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Matched sibling bone marrow transplantation (BMT) in severe aplastic anemia (SAA) has 
been known as the treatment of choice in children and young adults. To overcome graft 
failure, second stem cell transplantation showed good results in previous studies. Here 
we report two cases of aplastic anemia patients with late graft failure and resulted in 
successful complete recovery after selective CD34+ cell boost infusion. The patients pre-
viously underwent allogeneic BMT from HLA-matched sibling donors and the engraft-
ment was achieved although their CBC started to decrease respectively 3 months and 
11 months after transplantation. Both patients received selective CD34+ cell infusion with-
out additional conditioning therapy. Their CBC showed significant improvement and 
they are doing well without transfusion or complications. From this study we suggest 
that selected CD34+ cell boost treatment can be a promising curative treatment for late 
graft failure after matched sibling BMT in SAA patients.
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Introduction
HLA-matched sibling bone marrow transplantation (BMT) 
in severe aplastic anemia (SAA) has been known as the 
treatment of choice in children and young adults [1], al-
though graft failure occurs in 5-25% of patients after trans-
plantation [2]. Unlike primary graft failure which means no 
engraftment of donor cells, secondary graft failure is asso-
ciated with loss of donor chimerism after engraftment [3] 
showing marrow hypoplasia with a requirement of frequent 
transfusions [4]. To overcome graft failure which leads to 
increased mortality and morbidity, second stem cell trans-
plantation is suggested in several previous studies [3-5]. 
Cells of the same donor or other allogeneic donor have 
been used for the boost treatment, and moreover selective 
CD34+ cells are proposed to be a successful source of re-
infusion in graft failure [6].
We report our experience of the selective CD34+ cell 
boost treatment in two aplastic anemia patients who had 
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late graft failure after matched sibling BMT.
Case Reports
1) Case 1 
An 11-year-old girl underwent allogeneic BMT from her 
HLA (8/8) and ABO matched sister 11 months after the diag-
nosis of SAA. Fanconi anemia and other myelodysplastic 
syndromes were excluded. The conditioning therapy in-
cluded cyclophosphamide (50 mg/kg) for 4 days and an-
ti-thymocyte globulin (ATG) (2.5 mg/kg) for 3 days. Infused 
CD34+ cell dose was 1.4×106/kg of recipient. The engraft-
ment, which is defined as the first day of three consecutive 
days of more than 0.5×109/L of absolute neutrophil count 
(ANC), was achieved on day +22 and on day +25 bone mar-
row (BM) biopsy showed hypocellular marrow with com-
plete donor chimerism. The patient received granulocyte 
colony-stimulating factor from day +3 and cyclosporine and 
methotrexate were used for GVHD prophylasix. She had 
no symptoms and signs of acute graft versus host disease 
(GVHD). On post-transplant day +88, her CBC showed de-
creased result of WBC 1,880/μL, hemoglobin 9.1 g/dL, and 
platelets 2.9×103/μL. Day +99 BM biopsy showed hypo-
cellular marrow (cellularity of less than 5%) in complete do-
nor chimerism without change. Since then, her CBC steadily 
decreased, she started to require RBC and platelet trans-
fusions by 2 years after transplantation. Four years after 
BMT, her sister’s peripheral blood stem cells were collected 
for the treatment of late rejection. We used CliniMACS sorting 
device (Miltenyi Biotec) to select CD34+ cells at post-trans-
plant 52.4 months, CD34+ cells of 1.83×106/kg were infused 
as boost therapy. No additional conditioning drugs or GVHD 
prophylaxis were used and no complications occurred dur-
ing and after the infusion. Until now, by 2 years after the 
boost treatment, the patient is being well with stable 
engraftment.
2) Case 2
A 15-year-old girl who had a history of idiopathic aplastic 
anemia and sibling BMT visited our hospital under the diag-
nosis of late graft rejection. She was diagnosed as aplastic 
anemia at the age of 13, and received BMT from HLA 
matched (8/8) but ABO and Rh mismatched brother, in an-
other hospital. Conditioning regimen consists of cyclo-
phosphamide (50 mg/kg) for 4 days, ATG (2.5 mg/kg) for 
3 days and procarbazine (12.5 mg/kg) for 3 days was 
undergone. The CD34+ cells of 0.18×106/kg were infused 
and on day +16, ANC increased up to 0.5×109/L. Although 
the engraftment was successful the graft rejection was sus-
pected after 11 months of the BMT. Laboratory results at 
the time of her first visit to our clinic were as follows: WBC 
2,770/μL, hemoglobin 6.3 g/dL, and platelets 3.1×103/μL. 
She received regular check-ups in our outpatient clinic. 
During follow-up, her pancytopenia progressed and BM bi-
opsy showed hypocellular marrow (cellularity 10-20%) with 
complete donor chimerism. Five years after BMT, a dose 
of 8.38×106 selective CD34+ cells per recipient body weight 
were administered without conditioning and GVHD 
prophylasix. During the 1 year follow-up, she has shown 
recovery of cell counts with no complications or GVHD. 
Discussion
In this report, patients of SAA showed successful engraft-
ment after sibling BMT with full donor chimerism although 
sustained stabilized hematopoiesis was not successfully ach-
ieved during follow-up. We have chosen CD34+ cells boost 
treatment for rescue therapy, and two weeks after the boost 
infusion, patients’ CBC showed complete recovery. They 
have been being followed up in the outpatient clinic with-
out transfusion for 28 months (case 1) and 16 months (case 
2). Their CBC results after the boost treatment show sig-
nificant increase compared to the results before their boost 
treatment. In case 1, median WBC (2,490±959/μL vs. 5,149 
±1,072/μL, P＜0.001), median hemoglobin (6.6±1.4 g/dL 
vs. 10.5±1.6 g/dL, P＜0.001), and median platelets (3.52± 
1.27×103/μL vs. 8.28±3.57×103/μL) all increased. In case 
2, median WBC (3,113±474/μL vs. 3,636±555/μL, P=0.01), 
median hemoglobin (8.5±1.4 g/dL vs. 11.5±2.0 g/dL, P
＜0.001), median platelets (4.05±0.96×103/μL vs. 9.44± 
2.83×103/μL) showed similar results.
Graft rejection is one of the most life threatening compli-
cations of BMT. Low stem cell dose, patients receiving 
transplantation from an HLA-mismatched, from an un-
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related donor, T cell-depleted graft, viral or fungal infection 
after transplantation and GVHD are known factors that in-
crease incidence of graft failure [5,6]. To prevent graft fail-
ure, large doses of stem cell infusion, matched donor trans-
plantation, lesser transfusion to lower sensitization have 
been suggested although the cause of graft failure is still 
not well known and it is difficult to predict graft failure 
[4,7].
To overcome this condition, boost treatment or second 
hematopoietic stem cell transplantation is being performed. 
One of the option is reinfusion of stem cells from a same 
donor with or without preparative conditioning treatment 
or from an alternative donor. Nevertheless, prolonged pan-
cytopenia and additional conditioning regimens increase 
complications such as infections and GVHD resulting in 
poor prognosis of graft failure [3-5].
Selective CD34+ cells collected from peripheral blood are 
one of a graft source for the patients. Positive stem cell se-
lection was first developed for autologous transplantations 
in high risk patients of refractory and relapsing diseases. 
Along with the development of selection techniques and 
devices, it has been used for allogeneic transplantation in 
leukemia and myelodysplastic syndrome which have high 
risk factors of GVHD with or without graft failure [8]. This 
method was used to reduce the risk of GVHD, and similar 
results were observed in SAA patients, selective CD34+ cell 
infusion significantly decreased GVHD while slightly raised 
the risk of graft failure due to small amount of T cells 
[2,9-11]. To prevent graft failure with lesser risk of GVHD, 
highly selective and large numbers of CD34+ cell infusion 
has been shown to be a successful choice [2]. They were 
also useful for patients who had history of heavy trans-
fusions before transplantation, for patients with unrelated, 
mismatched or haploidentical donor in SAA. Large numbers 
of selected stem cells are thought to accelerate immune 
reconstitution.
Trakhtman et al. [6] reported a SAA patient with graft 
dysfunction after matched sibling BMT who showed mixed 
chimerism (95% of donor cell) in BM study, this resulted 
in reversion to full donor-type chimerism after second in-
fusion of CD34+ enriched peripheral blood cells. The pa-
tients experienced acute GVHD in spite of GVHD prophy-
laxis with mofetil mycophenolate and basiliximab. In this 
case, boost treatment was performed 3 months after BMT. 
Chung et al. [12] also reported similar result showing suc-
cessful peripheral blood stem cell rescue for 7 aplastic ane-
mia patients with late graft failure. Complete donor chimer-
ism was maintained at the time (median 9.2 months from 
the initial transplantation) of boost treatment. Cyclosporine 
A was used for GVHD prophylasix although 2 patients de-
veloped acute GVHD and 3 patients developed chronic 
GVHD. Larocca et al. [13] compared trilineage recovery and 
GVHD among three groups of patients with primary and 
secondary poor graft function following allogeneic stem cell 
transplantation. Among patients who received no further 
infusion, who received a boost of unmanipulated stem cells 
from original donor, and who received CD34+ selective 
stem cells, the third group showed significant better tiline-
age recovery (40% vs. 36% vs. 75%) and low incidence of 
acute GVHD (0% vs. 29% vs. 0%).
In our two cases, boost treatment using selective CD34+ 
cells in condition of secondary graft insufficiency showed 
successful results. BM was replaced with 100% donor cells 
and the boost treatment was performed 4 to 5 years after 
BMT as a result of late graft failure. The signs of graft fail-
ure were shown earlier after the transplantation (3 months 
and 11 months after, respectively) however boost treatment 
was done several years after as the need of transfusion 
increased. Since the patients showed complete donor chi-
merism, and CD34+ cell infusion showed lesser risk of acute 
GVHD [2,10,13], we performed rescue therapy without 
GVHD prophylaxis and they showed no complications. 
Due to the short duration of follow-up period, the develop-
ment of chronic GVHD is not discussed here although it 
should be monitored since there is higher risk of extensive 
chronic GVHD following boost cell infusion [12,13]. 
Few studies have discussed the role of boost treatment 
of purified selective CD 34+ cells in late graft failure after 
sibling BMT in children with aplastic anemia. This report 
suggest that selective CD 34+ cell boost treatment, without 
further conditioning or GVHD prophylaxis, can be a prom-
ising curative treatment in late graft failure of SAA patients 
who previously underwent sibling BMT.
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